Viking Therapeutics, Inc.
VKTX
$23.94
$0.341.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 73.64% | 54.97% | 4.70% | 4.63% | 113.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.89% | 34.08% | 43.45% | 65.91% | 44.38% |
| Operating Income | -57.89% | -34.08% | -43.45% | -65.91% | -44.38% |
| Income Before Tax | -43.94% | -10.68% | -15.73% | -40.06% | -25.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.94% | -10.68% | -15.73% | -40.06% | -25.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.94% | -10.68% | -15.73% | -40.06% | -25.80% |
| EBIT | -57.89% | -34.08% | -43.45% | -65.91% | -44.38% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -29.20% | 0.35% | -3.81% | -6.06% | 3.60% |
| Normalized Basic EPS | -29.17% | -0.07% | -3.79% | -6.10% | 3.57% |
| EPS Diluted | -29.20% | 0.35% | -3.81% | -6.06% | 3.60% |
| Normalized Diluted EPS | -29.17% | -0.07% | -3.79% | -6.10% | 3.57% |
| Average Basic Shares Outstanding | 11.41% | 11.08% | 11.49% | 32.04% | 30.50% |
| Average Diluted Shares Outstanding | 11.41% | 11.08% | 11.49% | 32.04% | 30.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |